Arvind Dasari, MD, MS, explains how to sequence radioligand therapy, cabozantinib, and everolimus in well-differentiated neuroendocrine tumors.
|Videos|November 22, 2013
Targeting KRAS in Colorectal Cancer
Author(s)Charles S. Fuchs, MD, MPH
Charles S. Fuchs, MD, MPH, director, Gastrointestinal Cancer Center, Dana-Farber Cancer Institute, discusses targeting KRAS in colorectal cancer.
Advertisement
Clinical Pearls
Charles S. Fuchs, MD, MPH, director, Gastrointestinal Cancer Center, Dana-Farber Cancer Institute, discusses targetingKRASin colorectal cancer.
- KRASis mutated in 40% of patients and defines who should get cetuximab or panitumumab
- Patients should be genotyped for all mutations inKRASandNRAS
- Defining drug targets against mutantKRAShas been impossible thus far
Advertisement
Related to this article
Ravi Parikh, MD, MPP, discusses the future of oncology practice, including real-world data, patient engagement, emerging technologies, and policy priorities shaping cancer care.
The NDA was completed for first-line zipalertinib plus platinum chemotherapy in EGFR exon 20 insertion NSCLC, based on phase 3 REZILIENT3 data showing improved PFS.
Renuka Iyer, MD, discusses clear documentation for AI ambient scribes and why multidisciplinary tumor boards remain essential in neuroendocrine tumor care.
Aman Chauhan, MD, reviews DAREON-7 data on obrixtamig plus chemotherapy in DLL3-positive neuroendocrine carcinoma, including response rates by DLL3 level.
Jacob Sands, MD, of Dana-Farber Cancer Institute, discusses survival gains, durability, and safety of tarlatamab plus durvalumab in the phase 3 DeLLphi-305 trial.
Updated phase 2 data showed a 60% ORR and 86% CNS ORR with frontline silevertinib in non-classical EGFR-mutant NSCLC; FDA discussion supported a phase 3 trial in 2027.
Renuka Iyer, MD, explains how NCCN is digitizing its guidelines with structured data to support AI tools, prior authorization, and point-of-care access.
Advertisement
Advertisement
Trending on Targeted Onc
1
FDA Approves Durvalumab-EV Combo, Expanding MIBC Treatment Options
2
New ACS Guidelines Push for Earlier Prostate Cancer Screening
3
Survey Highlights NMIBC Care Challenges Among US Military Service, Veterans
4
Dr Dasari on Sequencing RLT, Cabozantinib, and Everolimus in NETs
5